Clinical Trial Update: Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating pharmacogenomic and pharmacokinetic safety and potential cost savings for patients treated with fluoropyrimidines; study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Capecitabine (capecitabine)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Neoplasms | Phase 1 | Status: COMPLETED